Case report

Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis

DOUGLAS E LEMLEY, LEE M DELACY, LEONARD B SEEFF, KAMAL G ISHAK, AND DAVID J NASHEL

From the Divisions of Rheumatology, and Gastroenterology and Hepatology, Department of Medicine, Veterans Administration Medical Center and Georgetown University School of Medicine; and the Department of Hepatic Pathology, Armed Forces Institute of Pathology, Washington, DC, USA

SUMMARY A patient with rheumatoid arthritis developed hepatic veno-occlusive disease following the use of azathioprine. Although azathioprine induced veno-occlusive disease is suspected to occur more frequently in patients with autoimmune dysfunction, it has not previously been reported as a complication of treatment in rheumatoid arthritis. The mechanism responsible for this condition remains unknown.

Recent reviews of azathioprine induced hepatic veno-occlusive disease in recipients of a renal transplant suggest that this poorly recognised drug reaction occurs predominantly in patients with autoimmune dysfunction or among those with pre-existing liver disease. Our observation of a patient with rheumatoid arthritis (RA) and chronic hepatic necroinflammatory disease of uncertain aetiology, who was found to have histological features of hepatic veno-occlusive disease following the use of azathioprine, further supports this position.

Case report

In 1983 a 59 year old man with a history of remote alcohol abuse and duodenal ulceration reported the onset of polyarticular pain and swelling. Evaluation showed symmetrical synovial thickening, juxta-articular osteopenia and erosions, and a positive rheumatoid factor. Aspirin and numerous other non-steroidal anti-inflammatory drugs were given, without relief of symptoms. Later trials of sodium aurothiomalate, hydroxychloroquine, d-penicillamine, and prednisone were similarly ineffective.

Azathioprine (50 mg twice daily) was introduced in May 1985, and three months later was followed by the onset of vague abdominal discomfort. The patient denied recent use of alcohol and gave no history of recurrent melena or haematemesis. Although he previously had required blood transfusion, there was no known history of clinically apparent hepatitis, and he had never abused intravenous drugs. Physical examination was abnormal only for persistent synovial thickening. No pericardial rub was present, bowel sounds were active, there was no jaundice or enlargement of the liver or spleen, and the stool was negative for occult blood loss. Laboratory data showed white blood cell count 8.6×10^9/l, haemoglobin 132 g/l, and packed cell volume 0.40; alkaline phosphatase 1402 nmol s^{-1}/l (normal 217–650), total bilirubin 3.4 μmol/l (normal 0–17), alanine transaminase 408 nmol s^{-1}/l (normal 17–350), and aspartate transaminase 585 nmol s^{-1}/l (normal 117–450). An evaluation of the cause of these abnormalities was not made at that time. Rather, in the absence of clinically evident gastrointestinal or hepatic disease prednisone (10 mg every other day) and aspirin (325 mg four times a day) were continued, hydroxychloroquine (200 mg twice daily) was resumed, and azathioprine was increased (50 mg three times a day).

By December 1985 clinical evidence of portal hypertension was apparent. The patient was re-
Hepatic veno-occlusive disease in rheumatoid arthritis

343

Fig. 1 Liver biopsy specimen showing subtotal occlusion of a terminal hepatic venule (arrow heads). (Haematoxylin-eosin.)

ferred to the Veterans Administration Medical Center, Washington DC, where physical examination showed hepatomegaly, ascites, and peripheral oedema. Significant laboratory results were: alkaline phosphatase 6093 nmol·s⁻¹/l, total bilirubin 13·6 µmol/l, alanine transaminase 986 nmol·s⁻¹/l, and aspartate transaminase 1722 nmol·s⁻¹/l. Anti-smooth muscle and antimitochondrial antibodies were negative as were serological tests for hepatitis B. Coagulation functions were normal; tests for cytomegalovirus were not performed. All drugs except prednisone were discontinued. Ascites partially resolved with bed rest, and repeated hepatic biochemical parameters two weeks after admission were: alkaline phosphatase 4206 nmol·s⁻¹/l, total bilirubin 20·4 µmol/l, alanine transaminase 323 nmol·s⁻¹/l, and aspartate transaminase 585 nmol·s⁻¹/l.

Percutaneous biopsy of the liver showed the acute and chronic changes of veno-occlusive disease, with marked centrilobular congestion, sinusoidal dilatation, and scattered foci of non-thrombotic sclerosis of terminal hepatic venules with adjacent hepatocellular necrosis (Fig. 1). Mild periportal fibrosis and patchy piecemeal necrosis were also noted and were considered to be related to probable non-A, non-B hepatitis as the consequence of prior blood transfusion. No abnormalities of the portal vasculature were apparent (Figs 2a and 2b), and the biopsy specimen showed no evidence of vasculitis, amyloidosis, or nodularity.

Although active RA, mild ascites, and raised alkaline phosphatase values (3300–3800 nmol·s⁻¹/l) persist 30 months after treatment with azathioprine was stopped, there has been no clinical evidence of progressive portal hypertension despite subsequent trials of prednisone, sulindac, hydroxychloroquine, gold, and sulphasalazine.

Discussion

Azathioprine induced hepatic veno-occlusive disease has been reported as a complication of anti-rejection treatment in recipients of a renal transplant

group.bmj.com on November 7, 2017 - Published by http://ard.bmj.com/Downloaded from
terised by the triad of jaundice, hepatomegaly or right upper quadrant abdominal pain, and ascites or sudden weight gain. The diagnosis is difficult to establish. The spectrum of presenting symptoms is wide, ranging from mild abdominal discomfort to liver failure and death. Hepatic biochemical abnormalities are non-specific. Also, it is difficult to attribute the liver dysfunction exclusively to azathioprine in most subjects in whom it is used because of the simultaneous administration of other potentially hepatotoxic drugs.

Further confusing the issue is the intrinsic hepatic
dysfunction that occasionally develops owing to RA itself. It is usually benign with only modest increases of transaminases or histological evidence of mild perportal inflammation, but necrotising arteritis may occur within the liver in severe systemic disease. Nodular regenerative hyperplasia is relatively frequently in Felty’s syndrome, but it has been reported in simple RA only rarely. The hepatotoxicity of uncomplicated RA is more commonly drug related. Reversible hepatocellular or cholestatic abnormalities, or both, have been noted following the use of aspirin and other non-steroidal anti-inflammatory drugs, D-penicillamine, and gold. Azathioprine too may cause chemical evidence of liver dysfunction or nausea, vomiting, and abdominal pain when administered to patients with RA. Nodular regenerative hyperplasia has been reported once in a patient with RA treated with this drug. Until now, however, histological evidence of hepatic veno-occlusive disease has not been observed following its use in this population.

The abnormalities in serum enzymes noted in this patient indicate the presence of underlying chronic necroinflammatory disease. Although there was a positive history of drinking, alcohol use was not a plausible explanation for the enzyme abnormalities as the patient was now abstinent, the biochemical changes were not consistent with alcohol use, and the histology was not compatible. Thus although the aetiology of this disorder was not determined, the pattern of biochemical abnormalities and the presence of piecemeal necrosis (a histological change that is consistent with though not necessarily pathognomonic of chronic hepatitis) supported the diagnosis of chronic non-A, non-B hepatitis, particularly in view of previous blood transfusion.

Three cases of veno-occlusive disease proved by biopsy have been reported in association with systemic lupus erythematosus. DePinho et al noted the development of scleral icterus and raised hepatic biochemical parameters three weeks after the start of treatment with azathioprine (100 mg daily) in a young man with active systemic lupus erythematosus and renal failure. Biochemical abnormalities resolved within two weeks of the discontinuation of azathioprine. Katzka and colleagues described the onset of hepatomegaly, scleral icterus, and increased alkaline phosphatase and total bilirubin values after one year of azathioprine treatment (50 mg daily) in a man with inactive systemic lupus erythematosus who had undergone renal transplantation. Symptoms resolved upon cessation of azathioprine and recurred upon re-

challenge. Repeat liver biopsies were not performed in either of these patients. The role of azathioprine in the induction of veno-occlusive disease in systemic lupus erythematosus is brought into question by Pappas et al, however, who reported the development of clinical evidence of hepatic dysfunction in concert with histological evidence of veno-occlusive disease in a young woman with active systemic lupus erythematosus who had neither undergone renal transplantation nor received azathioprine. A brief trial of azathioprine failed to affect her ascites, and repeat liver biopsy showed no significant changes following the azathioprine treatment. The authors concluded that the pathogenesis of veno-occlusive disease in systemic lupus erythematosus is unknown but postulated that it may be related to underlying vasculitis.

The development of azathioprine induced hepatic veno-occlusive disease has been associated with either pre-existing autoimmune dysfunction or liver damage, but a mechanism for the establishment of this vascular abnormality remains unknown. The presence of both immunological defects and incidental liver damage (as a result of possible viral hepatitis or the effects of alcohol ingestion, or both) in this case supports this position, but it unfortunately does not provide a better definition of the pathogenesis of veno-occlusive disease. It seems unlikely that RA alone contributes to the establishment of this disorder. Despite years of experience with azathioprine in RA, veno-occlusive disease has never previously been reported in this population. Although no true association between these entities may in fact exist, it is also possible that the lack of more frequent recognition of azathioprine induced veno-occlusive disease in RA reflects the usual benignity of hepatic pathology in RA, as well as the subtle histological features and variable presenting symptoms which may characterise hepatic veno-occlusive disease. Additionally, the role of pre-existing abnormalities of hepatic structure or function, perhaps resulting in altered metabolism of azathioprine and the subsequent development of veno-occlusive disease independent of autoimmune phenomena, cannot be excluded.

Thus administration of azathioprine should be attended with knowledge of the serious consequences that may occur with it use. It should be discontinued immediately in any patient who develops hepatic biochemical abnormalities, hepatomegaly, or other clinical evidence of portal hypertension, and a liver biopsy should be performed to confirm the presence of veno-occlusive disease. Heightened awareness of this potentially fatal complication in patients with RA who are treated with azathioprine may increase the frequency of its diagnosis.
References
Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis.

D E Lemley, L M DeLacy, L B Seeff, K G Ishak and D J Nashel

doi: 10.1136/ard.48.4.342

Updated information and services can be found at:
http://ard.bmj.com/content/48/4/342

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/